The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure the full implications, economic and social, of living with rare disease in the United States. People with rare diseases know that the impacts of such conditions extend beyond just medical…
News
The Pulmonary Hypertension Association (PHA) is inviting the patient community to participate in its virtual fashion show, set for Aug. 1, as part of its “PHA Connects: Summer PHling.” The fashion show, which has been featured for years at the PHA’s International PH Conference and…
Janssen Korea and Johnson & Johnson Innovation have launched an initiative to help advance breakthrough innovations to improve patient care during the COVID-19 pandemic, including those that can potentially diagnose pulmonary hypertension rapidly and early. The initiative, named “Seoul Innovation QuickFire Challenge for Healthcare in the…
Tyvaso (inhaled treprostinil) significantly improved the exercise capacity of people with World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD), achieving its primary endpoint in the…
Sotatercept (ACE-011) leads to clinically meaningful reductions in heart strain and improvements in functional capacity in patients with pulmonary arterial hypertension (PAH), top-line data from a Phase 2 trial show. The findings were presented in an oral presentation, titled “Sotatercept for…
Anodal block, a technique based on electrical nerve stimulation, allows for the selective activation of fibers in the vagus nerve, a key nerve that runs through the neck and controls the workings of the heart and lungs, an early study in mice reported. A more controlled activation of the vagus…
Newborns were seen to be at an increased risk of pulmonary hypertension (PH) if they developed poorly while in the womb and had meconium aspiration syndrome, meaning they inhaled their feces during birth, a study from Pakistan reported. The…
The Alexion Charitable Foundation has awarded $1.1 million in grants to programs that support those with rare diseases during the COVID-19 pandemic, the organization recently announced. The grants will support activities that align with the foundation’s Rare Belonging focus, a set of funding priorities aimed at improving the…
Increasing the levels of a tiny RNA molecule known as microRNA-483 enhanced the function of endothelial cells and eased the symptoms of pulmonary arterial hypertension (PAH) in rat models of the disease, a new study shows. The results support the potential of microRNA-483 as a potential therapy for PAH. The study,…
Gene expression patterns in the lungs can help distinguish pulmonary arterial hypertension (PAH) from pulmonary veno-occlusive disease (PVOD) — a subtype in which the narrowing of veins, instead of arteries, causes pulmonary hypertension — with high accuracy, a study reported. Findings also showed that lung diseases share similar alterations…
Kalytera Therapeutics has announced positive early results for R-107, a liquid form of nitric oxide designed to treat pulmonary arterial hypertension (PAH) associated with COVID-19. Nitric oxide, known as NO, is a gas naturally present in the…
Aerami Therapeutics has entered an agreement with Vectura Group to develop and commercialize an inhaled form of imatinib — an approved cancer therapy — for the treatment of people with pulmonary arterial hypertension (PAH). Under the agreement, Aerami will be solely responsible for developing this new…
